Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James Louis Januzzi Jr., M.D.


This page shows the publications co-authored by James Januzzi and Jagmeet Singh.
Connection Strength

  1. Ibrahim NE, Desai AS, Singh JP, Januzzi JL. Advances in Heart Failure Management: Improving Outcomes With Innovation. Rev Cardiovasc Med. 2017; 18(S1):S1-S16.
    View in: PubMed
    Score: 0.192
  2. Truong QA, Januzzi JL, Szymonifka J, Thai WE, Wai B, Lavender Z, Sharma U, Sandoval RM, Grunau ZS, Basnet S, Babatunde A, Ajijola OA, Min JK, Singh JP. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm. 2014 Dec; 11(12):2167-75.
    View in: PubMed
    Score: 0.162
  3. Martin LM, Januzzi JL, Thompson RW, Ferris TG, Singh JP, Bhambhani V, Wasfy JH. Clinical Profile of Acute Myocardial Infarction Patients Included in the Hospital Readmissions Reduction Program. J Am Heart Assoc. 2018 08 21; 7(16):e009339.
    View in: PubMed
    Score: 0.054
  4. Arrigo M, Truong QA, Szymonifka J, Rivas-Lasarte M, Tolppanen H, Sadoune M, Gayat E, Cohen-Solal A, Ruschitzka F, Januzzi JL, Singh JP, Mebazaa A. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. Europace. 2017 Nov 01; 19(11):1848-1854.
    View in: PubMed
    Score: 0.051
  5. Arrigo M, Truong QA, Onat D, Szymonifka J, Gayat E, Tolppanen H, Sadoune M, Demmer RT, Wong KY, Launay JM, Samuel JL, Cohen-Solal A, Januzzi JL, Singh JP, Colombo PC, Mebazaa A. Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study. Clin Chem. 2017 Jan; 63(1):386-393.
    View in: PubMed
    Score: 0.047
  6. Beaudoin J, Singh JP, Szymonifka J, Zhou Q, Levine RA, Januzzi JL, Truong QA. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study. Can J Cardiol. 2016 12; 32(12):1478-1484.
    View in: PubMed
    Score: 0.046
  7. Chatterjee NA, Singh JP, Szymonifka J, Deaño RC, Thai WE, Wai B, Min JK, Januzzi JL, Truong QA. Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study. Int J Cardiol. 2016 Feb 15; 205:43-49.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.